UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 6, 2023

Immuneering Corporation (Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation)

001-40675 (Commission File Number)

26-1976972 (IRS Employer Id -cation No.)

245 Main St.

Second Floor Cambridge, MA 02142

ess of principal executive offices) (Zip Code) (617) 500-8080 ber, include area code) (Registrant's telepho

(Registrant's telephone number, include area code) N/A ner Name or Former Address, if Changed Since Last Report) (For

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

(Add

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class Class A common stock, par value \$0.001 per share Trading Symbol(s) Name of each exchange on which registered _ _

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 🗵

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On March 6, 2023, Immuneering Corporation (the "Company") announced its financial results for the quarter and full-year ended December 31, 2022 and provided business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report").

The information in this Item 2.02 of this Current Report, including Exhibit 99.1, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

On March 6, 2023, the Company posted an updated corporate slide presentation in the "For Investors" portion of its website at www.immuneering.com. A copy of the slide presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report, including Exhibit 99.2, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits relate to Items 2.02 and 7.01, which shall be deemed to be furnished, and not filed:

Exhibit	
No.	Description
99.1	Press Release issued on March 6, 2023
99.2	Immuneering Corporation Corporate Slide Presentation as of March 6, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNEERING CORPORATION

Date: March 6, 2023

By: /s/ Benjamin J. Zeskind Name: Benjamin J. Zeskind, Ph.D. Title: Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)



Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation

Provides debut guidance for IMM-1-104 program: initial Phase 1 PK and safety data expected in mid-2023, initial Phase 1 PD modeling and additional PK and safety data expected in 2H 2023, recommended phase 2 dose and additional safety data expected in mid-2024

Continued progress in oncology pipeline - on track to file IND for IMM-6-415 in Q4 2023

Cash runway extended into Q4 2024; sharpened focus on oncology pipeline and suspension of discovery-stage neuroscience programs

Conference call and webcast today at 4:30 p.m. ET.

CAMBRIDGE, Mass., March 6, 2023 -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business updates.

"2022 was a year of important progress towards our goal of creating impactful new medicines for cancer patients," said Ben Zeskind, Ph.D., MBA, Cofounder, and Chief Executive Officer of Immuneering. "IMM-1-104, the first and only MAPK pathway inhibitor with the potential for universal-RAS activity, entered the clinic as we dosed the first patient in our Phase 1/2a clinical trial in November, enrolling patients with advanced solid tumors harboring RAS mutations. With a unique and counterintuitive mechanism of deep cyclic inhibition, IMM-1-104 was designed to limit toxicity and maximize therapeutic activity by selectively targeting cancer cells based on their increased need for sustained MAPK pathway signaling, while sparing healthy cells which are less dependent on continuous pathway signaling. IMM-1-104 is being evaluated as an oral, once-daily monotherapy. Our goal is to provide newer and better treatment options for patients with tumors driven by *any* mutation in KRAS, NRAS, or HRAS."

Dr. Zeskind continued: "We are very pleased with the progress of our trial, which enables us today to provide debut guidance on when investors can expect to see initial data from our ongoing IMM-1-104 Phase 1/2a clinical trial. Currently, we plan to share (1) initial Phase 1 pharmacokinetic (PK)

ii Immuneering

and safety data in mid-2023, followed by (2) initial Phase 1 pharmacodynamic (PD) modeling and additional PK and safety data in the second half of 2023 and (3) the announcement of a recommended Phase 2 dose and additional safety data in mid-2024. We also plan to provide additional trial updates on a periodic basis. Because observing a unique PK profile in humans is a fundamental aspect of our counterintuitive deep cyclic inhibition mechanism, we believe these initial readouts could provide particularly impactful early validation for our approach and the potential universal-RAS activity of IMM-1-104. With our clinical trial rapidly advancing and continued progress accelerating IMM-6-415 toward an IND filing later this year, we have also taken the opportunity to sharpen our focus exclusively to oncology, by suspending our neuroscience programs. This change as well as other non-core adjustments extend our projected cash runway by an additional quarter, into Q4 2024."

Corporate Highlights

- Preclinical data on lead program IMM-1-104 presented at American Association for Cancer Research (AACR) special conference targeting RAS: In March 2023, Immuneering presented preclinical data in a poster titled, "Pan-RAS IMM-1-104 activity in humanized 3D tumor models is independent of specific amino acid substitution." IMM-1-104 demonstrated response across RAS mutant preclinical models regardless of mutation position or amino acid substitution, suggesting potential relevance to a broad universal-RAS-driven patient population.
- Cash runway extended into Q4 2024 with sharpened focus on oncology pipeline: In March 2023, Immuneering announced the company would sharpen its focus exclusively to its oncology pipeline, suspending its discovery-stage neuroscience programs. With this change, and other non-core adjustments, based on cash, cash equivalents and marketable securities and current operating plans, the company now expects its cash runway to extend into the fourth quarter of 2024.
- First patient dosed in Phase 1/2a Clinical Trial of IMM-1-104 in advanced solid tumors with RAS mutations: In September 2022, Immuneering received FDA clearance of the IND application for IMM-1-104 and in November 2022, commenced dosing in a Phase 1/2a open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of IMM-1-104 as an oral, once-daily monotherapy in patients with advanced RAS mutant solid tumors. To the company's knowledge, this is the first and only clinical trial for which patients with *any* mutation in KRAS, NRAS, or HRAS are eligible to be screened for other enrollment criteria. The Phase 1 portion of the study, which is being conducted at five clinical sites in the United States, includes a dose escalation phase and dose evaluation phase in order to establish an optimized Recommended Phase 2 Dose (RP2D) candidate. Subject to Phase 1 results, the Company currently expects to conduct a



Phase 2a dose expansion phase in order to assess the safety and efficacy of IMM-1-104 at the RP2D in RAS mutated pancreatic, melanoma, lung, and colorectal cancers. The Company is currently in the dose escalation phase of the trial.

- Preclinical data on its second program IMM-6-415 presented at the 37th Annual Meeting of SITC: In November 2022, Immuneering presented
 preclinical data in a presentation titled, "Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the Dual MEK inhibitor,
 IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors." IMM-6-415 exhibited preclinical activity as a single-agent in
 RAF and RAS mutant tumor models, as well as enhanced activity in combination with checkpoint inhibitors (CPIs) in RAS-mutant colorectal cancer
 (CRC) and non-small cell lung cancer (NSCLC) models driven by diverse MAPK pathway mutations.
- Chief People Officer appointed: In October 2022, the company announced the appointment of Leah R. Neufeld to the newly created Chief People Officer position. Ms. Neufeld brings decades of experience in life sciences as well as human resources and will join the senior leadership team in continuing to make the company a great place for the all-star team of Immuneers to work and grow, while also helping to add new talent as the company advances a robust pipeline of novel product candidates.
- Preclinical data presented at ASCO 2022 Annual Meeting highlighting pan-KRAS/NRAS activity of IMM-1-104: In May 2022, Immuneering
 presented two preclinical abstracts. The first abstract, titled "Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus sotorasib or
 adagrasib in KRAS mutant pancreatic tumors," demonstrated a lack of Tumor Growth Inhibition (TGI) by sotorasib and adagrasib in KRAS-G12V
 mutant Capan-2 PDAC tumors. In contrast, IMM-1-104 observed TGIs of 49-84% across all doses and schedules tested. Consistent with other
 IMM-1-104 *in vivo* studies, median body weight loss was no more than 3-5% at top doses. The second abstract titled "Translational modeling for
 patients with RAS mutant tumors: Profiling the dual-MEK inhibitor IMM-1-104 in a humanized 3D assay," found KRAS mutant pancreatic cancer
 and NRAS mutant melanoma were the most broadly sensitive patient-aligned models in the 3D-tumor growth assay and are expected to be
 included among the target indications planned for the Phase 2a portion of Immuneering's ongoing Phase 1/2a clinical trial.



Near-Term Milestone Expectations

IMM-1-104

- Initial Phase 1 PK and safety data expected in mid-2023
- Initial Phase 1 PD modeling data and additional PK and safety data expected in the second half of 2023
- Recommended Phase 2 dose and additional safety data expected in mid-2024
- Additional trial updates expected on a periodic basis

IMM-6-415

• IND filing expected in the fourth quarter of 2023

Fourth Quarter and Full Year 2022 Financial Highlights

- Cash Position: Cash, cash equivalents and marketable securities as of December 31, 2022 were \$105.5 million, compared with \$150.2 million as of December 31, 2021.
- Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2022 were \$9.9 million compared with \$7.9 million for the fourth quarter of 2021. Full year 2022 R&D expenses were \$36.3 million compared to \$26.5 million for full year 2021. The increase in R&D expenses from both periods of 2021 was primarily attributable to higher clinical costs related to the company's lead program and increased personnel to support ongoing research and development activities.
- General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2022 were \$4.1 million compared with \$3.1 million for the same period of 2021. Full year 2022 G&A expenses were \$15.6 million compared to \$8.3 million for full year 2021. The increase in G&A expenses for both periods of 2022 was primarily attributable to an increase in headcount in the company's general and administrative functions to support the business, and costs related to operating as a public company.
- Net Loss: Net loss attributable to common stockholders was \$13.2 million, or \$0.50 per share, for the quarter ended December 31, 2022, compared to \$10.8 million, or \$0.42 per share, for the quarter ended December 31, 2021. Net loss attributable to common stockholders for full year 2022 was \$50.5 million, or \$1.91 per share compared to \$33.5 million, or \$2.46 per share, for full year 2021.



2023 Financial Guidance

• Based on cash, cash equivalents and marketable securities, as of December 31, 2022, and current operating plans, the company expects its cash runway to extend into the fourth quarter of 2024.

Conference Call

Immuneering will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on March 6, 2023, to discuss the results and provide a business and pipeline update. To access the call by phone, please use this registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. After the live webcast, the event will be archived for 90 days in the Investor Relations section of Immuneering's website at Events & Presentations.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering's lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company's development pipeline also includes IMM-6-415, our universal-MAPK inhibitor, as well as several early-stage programs. For more information, please visit <u>www.immuneering.com.</u>

Forward-Looking Statements

This press release includes certain disclosures that contain "forward-looking statements," including, without limitation, statements regarding Immuneering's expectations regarding the sufficiency of Immuneering's cash, cash equivalents and marketable securities, current operating plans and cash runway, the treatment potential of IMM-1-104 and IMM-6-415, including estimates of the patient population that may ultimately benefit from treatment, statements regarding the design, enrollment and conduct of the Phase 1/2a clinical trial for IMM-1-104, the timing of initial Phase 1 PK and safety data, initial PD modeling data and additional PK and safety data, additional trial updates, recommended phase 2 dose and additional safety data, the ability of initial readouts to validate the company's therapeutic approach, the timing of submission of the IND for IMM-6-415, and

Immuneering

Immuneering's ability to advance its pipeline and further diversify its portfolio and make progress towards its longstanding goal of creating better medicines for cancer patients. Forward-looking statements are based on Immuneering's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including target discovery, target validation, lead compound identification, lead compound optimization, preclinical studies and clinical trials. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in Immuneering's most recent Form 10-K filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Immuneering undertakes no duty to update such information except as required under applicable law.

Media Contact: Gina Nugent Nugent Communications 617-460-3579 gina@nugentcommunications.com

Investor Contact:

Laurence Watts Gilmartin Group 619-916-7620 laurence@gilmartinir.com



IMMUNEERING CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Er	nded De	cember 31		Twelve Months E	nded De	cember 31
	 2022		2021		2022		2021
Revenue	\$ 456	\$	189,591	\$	316,952	\$	2,079,961
Cost of revenue	 		206,221		158,122		1,153,073
Gross profit	 456		(16,630)		158,830		926,888
Operating expenses							
Research and development	9,871,761		7,950,488		36,267,116		26,540,959
General and administrative	4,106,385		3,148,637		15,606,529		8,271,998
Amortization of intangible asset	7,317		_		30,053		_
Total operating expenses	 13,985,463	-	11,099,125		51,903,698		34,812,957
Loss from operations	(13,985,007)		(11,115,755)		(51,744,868)		(33,886,069)
Other income (expense)							
Interest income	516,167		142,885		1,014,456		169,899
Other income (expense)	223,278		(118,974)		216,844		(127,063)
Loss before income taxes	 (13,245,562)	_	(11,091,844)		(50,513,568)		(33,843,233)
Income tax benefit	_		307,485		_		307,485
Net loss	\$ (13,245,562)	\$	(10,784,359)	\$	(50,513,568)	\$	(33,535,748)
Net loss per share attributable to common stockholders, basic and diluted	(0.50)		(0.42)		(1.91)		(2.46)
Weighted-average common shares outstanding, basic and diluted	 26,406,933		25,977,246	_	26,386,864		13,612,677
Other comprehensive loss:							
Unrealized losses from marketable securities	112,353		(44,258)		18,889		(49,009)
Comprehensive Loss	\$ (13,133,209)	\$	(10,828,617)	\$	(50,494,679)	\$	(33,584,757



IMMUNEERING CORPORATION

CONSOLIDATED BALANCE SHEETS

(Unaudited)

	De	cember 31, 2022	D	ecember 31, 2021
Assets				
Current assets:				
Cash and cash equivalents	\$	72,636,886	\$	74,888,145
Marketable securities, current		32,887,970		74,311,203
Accounts receivable		12,417		246,040
Prepaids and other current assets		3,209,536		2,888,608
Total current assets		108,746,809		152,333,996
Marketable securities, non-current		_		996,560
Property and equipment, net		1.369.608		807.223
Goodwill		6.690.431		6,701,726
Intangible asset		408,947		439,000
Right-of-use assets, net		4,407,785		5.324.198
Other assets		743,703		102,129
Total assets	\$	122,367,283	\$	166,704,832
Liabilities, convertible preferred stock and stockholders' equity				
Current liabilities:				
Accounts payable	\$	3,154,557	\$	1,394,340
Accrued expenses		4,500,993		3,965,447
Other liabilities, current		19,796		_
Lease liabilities, current		378,723		274,039
Total current liabilities		8,054,069		5,633,826
Long-term liabilities:				
Lease liabilities, non-current		4,462,959		5,090,897
Total liabilities		12,517,028		10,724,723
Commitments and contingencies (Note 13)				, , , ,
Stockholders' equity:				
Preferred stock, \$0.001 par value; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021; No shares issued or outstanding		-		-
Class A common stock, \$0.001 par value, 200,000,000 shares authorized at December 31, 2022 and December 31, 2021; 26,418,732 and 26,320,199 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively		26,419		26,320
Class B common stock, \$0.001 par value, 20,000,000 shares authorized at December 31, 2022 and December 31, 2021; 0 shares issued and outstanding at December 31, 2022 and December 31, 2021		_		—
Additional paid-in capital		219,640,912		215,276,186
Accumulated other comprehensive loss		(30,120)		(49,009)
Accumulated deficit		(109,786,956)		(59,273,388)
Total stockholders' equity		109,850,255		155,980,109
Total liabilities, convertible preferred stock and stockholders' equity	\$	122,367,283	\$	166,704,832

Building a Universal-RAS Franchise

i Immuneering

Nasdaq: IMRX

MARCH 2023

With the potential to benefit more than 1.5 million cancer patients

FORWARD-LOOKING STATEMENTS AND OTHER DISCLAIMERS

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding Immuneering Corporation's (the "Company") plans to develop, manufacture and commercialize its product candidates, the timing or outcome (including interim results) of the Company's ongoing or planned clinical trials for IMM-1-104, including our Phase 1/2a clinical trial, any of the Company's other pipeline product candidates and any future product candidates, the clinical utility of the Company's product candidates and treatment potential, the ongoing impact of the COVID-19 pandemic on the Company's business and operations, including manufacturing, research and development, clinical trials and employ the Company's cash needs and availability, projected cash runway and current operating plans, and the plans and objectives of management for future operations.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation: our ability to successfully complete our Phase 1/2a clinical trial, or any planned clinical trials and for those trials to produce positive results, our estimates of the number of patients who suffer from the diseases we are targeting and benefit from the medicines we are developing, and the number of patients that may enroll in our clinical trials; o ability to file INDs in the future; the commercializing of our product candidates, if approved; the timing of the initiation, progress and potential results of our ongoing and planned preclinical studies and clinical trials and our research programs, including our Phase 1/2a clinical trial; our ability to advance additional product candidates into, and successfully complete, preclinical studies and clinical trials with those additional product candidates; the timing or likelihood of regulatory filings and approvals; our product candidates for clinical trials and for commercial use, if approved; future strategic arrangements and/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenue, capital requirements and needs for financi and our ability to obtain capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified professionals; the implementation of our business model, strategic plans for our business and product candidates; our compliance with laws, the scope of protection we are able establish and maintain for intellectual property rights, product candidates and our pipeline; our ability to contract with third-party suppliers and manufacture and their ability to perform adequately; the pricing, coverage and reimbursement of our product candidates, if approved; and developments rela

These and other important factors discussed under the caption "Risk factors" in the Company's most recent periodic filing with the Securities and Exchange Commission (SEC) and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statement made in this presentation. Any such forward-looking statements represent management's estimates as of the date of this presentation. While the Company n elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation.

2023 Corporate Presentation



Investment Summary

"Our approach is different."

- Targeting **large Universal-RAS** patient population (1.5M) versus more limited approaches.
- **Monotherapy** vs combination therapy potential
- Deep cyclic inhibition achieved briefly but forcefully, due to combination of:
 - Manyfold higher C_{MAX}
 and short half life
- Approach designed to spare healthy cells and potential to limit adaptive resistance.

3 2023 Corporate Presentation

"IMM-1-104 demonstrates Universal-RAS potential."


- Robust preclinical activity
 observed in:
 - Pancreatic Cancer (KRAS^{G12C & G12V)}
 - NSCLC (KRAS^{G125}
 - CRC (KRAS^{G12D)}
 - Melanoma (NRAS^{Q6IR}
 - And others
- Hypothesis for IMM-1-104 from proprietary model.
- Validated using proprietary bioinformatics & 3D tumor growth assays


"2023 is shaping up to be our breakout year."

- **First patient dosed** in Phase 1/2a trial of lead asset IMM-1-104 in November 2022.
- Patient enrollment ongoing; investigator enthusiasm high.
- Broad inclusion criteria facilitates rapid trial enrollment.
- Upcoming data readouts, beginning mid-2023
- Cash runway projected into Q4 2024

IMM-1-104's Potential ...

4





Development Pipeline

Wholly Owned Product Portfolio Differentiated by Indication and Half-life

PROGRAM	INDICATION	DISCOVERY	IND- ENABLING	PHASE 1	PHASE 2	PHASE 3	MILESTONE
IMM-1-104	Universal-RAS	Once Daily (QD))				Phase 1/2a Tri Enrolling; initial P safety data expect 2023
IMM-6-415	Universal-MAPK	Twice Daily (BI	D)				IND filing in Q4
		Multip	le additional p	programs in dis	scovery phase		

Cash, cash equivalents and marketable securities of \$105.5M as of December 31, 2022 expected to fund operations into Q4 2024

6 2023 Corporate Presentation

IMM-1-104



IMM-1-104

- Potential for Universal-RAS Activity
- Deep Cyclic Inhibition; Once-Daily Oral Dosing
- Short plasma half-life to minimize drug trough
- Initially being developed as Monotherapy
- Designed to Resist CRAF-bypass in RAS mutant tumors
- Phase 1 recruiting all-comer RAS solid tumors: <u>NCT05585320</u>
- First patient dosed November 2022
- Robust pre-clinical activity observed in 6 different animal models; well-tolerated (median body weight loss of less than 3-6% at top doses)

8 2023 Corporate Presentation

IMM-1-104 Demonstrates Universal-RAS Potential

132 Tumor Models	Tissue	Response #	Non-Response #	RAS, RAF mutation	Response #	Non-Response	
75 = RAS Mutant	Pancreatic †	17	2	NRAS G12	2	0	
	Melanoma †	22	0	NRAS G13	1	0	
	Lung ⁺	19	6	NRAS Q61	17	2	
	CRC	20	5	KRAS A146	1	0	
	Thyroid	6	1	KRAS G12	36	8	
0 0 0 0 0	Soft Tissue	2	1	KRAS G13 ^	3	1	
	Breast	2	6	KRAS Q61	3	0	
	Gastric	4	2	HRAS G13 *	1	0	
Humanized	Ovary	3	2	BRAF (Class I or II)	21	4	
3D-TGA	Prostate	1	2	Total	85 (85.0%)	15 (15.0%)	
3D-10A	Fibrosarcoma	1	0				
	Liver	4	2	RAS, RAF mutation	Response #	Non-Response	
Kolitz, et al. 2023	Neuroblastoma	1	1	Not Present	17	15	
AACR: Targeting RAS Philadelphia, PA	Total	102 (77.3%)	30 (22.7%)	Total	17 (53.1%)	15 (46.9%)	

^ 1 model also bearing KRAS Q61 /// * 1 model also bearing NRAS Q61


Response to IMM-1-104 based on 3D-TGA and other preclinical modeling. Parallel translational efforts are focused on projecting patient-aligned molecular profiles or 'Targetability'.

Models tested in 3D-TGA were assigned responsive if dose response IC50 < 1uM (sensitive) or IC50 ≥ 1 with >25% reduction at 10uM (intermediate), and non-responsive otherwise (resistant) † Select 3D-TGA models: (1.) Pancreatic MIA PaCa-2 (sensitive/responsive), (2.) Pancreatic Capan-2 (intermediate/responsive), (3.) Melanoma SK-MEL-2 (sensitive/responsive), (4.) Lung A549 (intermediate/responsive)

9

2023 Corporate Presentation


IMM-1-104 Demonstrates Universal-RAS Potential



10 2023 Corporate Presentation

Pancreatic: Head-to-Head Comparison of IMM-1-104 +/- Sotorasib in a KRAS-G12C Pancreatic Tumor Model

IMM-1-104 as compared to sotorasib demonstrated tumor regression, both with insignificant BWL



MIA PaCa-2 (KRAS^{GI2C}) Pancreatic Xenograft Tumor Model in Athymic Nude Mice


> Sotorasib was commercially purchased

Tumor Growth Inhibition (TGI) % = $[1 - (T_i - T_o)/(C_i - C_o)]$ x100 Expanded TGI formula vs. previous 1-[T/C]x100% method

1] 2023 Corporate Presentation

Pancreatic: Head-to-Head Comparison of IMM-1-104 vs. Sotorasib and Adagrasib in a KRAS-G12V Pancreatic Tumor Model

IMM-1-104 demonstrated tumor regression as compared to sotorasib or adagrasib, with insignificant BWL



12 2023 Corporate Presentation


Melanoma: Phase 3 NEMO Study: Binimetinib vs. Dacarbazine (NRAS^{mut} Melanor

Overall **Progression Free** * 1 Survival Survival **NRAS Status** Binimetinib 2:1 Dacarbazine 2.8 months 11.0 months **Binimetinib** N = 269 N = 133 0.62 1.00 Hazard Ratio Q61K 100 (37%) 51 (38%) Q61L 32 (12%) 17 (13%) Dacarbazine 1.5 months 10.1 months Q61R Serious Adverse Events (34% binimetinib vs. 22% dacarbazine) > Wildtype 0 1 (1%) Overall Response Rate (ORR: 15% binimetinib vs. 7% dacarbazine) > Dummer, et al 2017 Lancet S1470-2045 (17) 30180-8 <u>ii</u> Immuneering 13 2023 Corporate Presentation

Summary of phase 3 data from the NEMO study as reported in Lancet (c.2017)

Melanoma: Head-to-Head NRAS-Q61R Melanoma Xenograft Study: Binimetinib vs. IMM-1-104 in SK-MEL-2

IMM-1-104 as compared to binimetinib monotherapy demonstrated greater tumor growth inhibition (TGI)




14 2023 Corporate Presentation


Binimetinib was commercially purchased

CRC: Head-to-Head Comparison of IMM-1-104 Against Selumetinib and Binimetinib in a KRAS-G12D CRC Syngeneic Mouse Tumor Model

IMM-1-104 demonstrated greater tumor growth inhibition (TGI), lower body weight loss (BWL) and greater durability via reductions in tumor volume



IMM-1-104: Phase 1/2 Clinical Trial Plan



Phase 1 Sites

A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

United States, California	City of Hope Duarte, California, United States, 91010 Principal Investigator: Vincent Chung, MD	
United States, New York	MD Weill Cornell Medicine > New York, New York, United States, 10021 > Principal Investigator: Anna Pavlick, DO	
United States, Texas	MD Anderson Cancer Center Houston, Texas, United States, 77030 Principal Investigator: Shubham Pant, MD	NEXT Oncology > San Antonio, Texas, United States. 78229 > Principal Investigator: David Sommerhalder, MD
United States, Virginia	NEXT Oncology > Fairfax, Virginia, United States, 22031 > Principal Investigator: Alex Spira, MD, PhD	

Upcoming Potential Milestones


Program	Milestone	Expected Timing
IMM-1-104	Initial Phase 1 pharmacokinetic (PK) and safety data	Mid-2023
IMM-1-104	Initial Phase 1 pharmacodynamic (PD) modeling data and additional PK and safety data	2H 2023
IMM-1-104	RP2D and Safety data	Mid-2024
IMM-1-104	Additional trial updates	On a periodic basis
IMM-6-415	IND filing	4Q 2023

18 2023 Corporate Presentation

IMM-6-415



IMM-6-415: Monotherapy Activity in RAF and RAS Mutant Tumors



20 2023 Corporate Presentation

Accelerated Cadence of IMM-6-415 Enhances Activity of Checkpoint Inhibitors

KRAS^{G12D} CRC

Schedule	Dose (mg/kg)	Veh	αPD-1 (BIW)	αCTLA-4 (BIW)	IMM-6-415	IMM-6-415 + PD-1	IMM-6-415 + CTLA-4		by of Survival	
BID		10/12		Jo Allindedor	120 mg/kg BID 415					
BID	60	0/12			0/12	8/12	8/12		20-	-I. BIW-Isotype-PD-1 -I. 0 mg/kg BIW PD-1 -I. 120 mg/kg BID 415 + PD-1
BID	30	0/12			0/12	5/12	5/12		0	0 2 4 6 8 10 12 14 16 18 20 22 24 26
QD				Days N = 12 mice p						
QD		1->	100-							
QD	30	0/12			0/12	6/12	7/12		90-	CTLA4
BIW	10	0/12	4/12						of Survival	-
BIW	10	0/12		4/12					Probability of	BID-Vehicle
 Number of through Date 	BALB/c mice y 28 with volu					erapy Treated ation ≥ 3 Adva	Alive at Day 28 Intage		20- 10-	BW-3exbps-CTLA4 ncl: p = 0.1970 -L 10 mg/kg BW CTLA4 ncl: p = 0.1970 -L 12 mg/kg BW CTLA4 ncl: p = 0.1970 -L 12 mg/kg BW CTLA4 ncl: p = 0.1970 -L 12 mg/kg BW CTLA4 ncl: p = 0.1970 -L 12 mg/kg BW CTLA4 ncl: p = 0.1970 -L 12 mg/kg BW CTLA4 ncl: p = 0.1970 -L 12 mg/kg BW CTLA4 ncl: p = 0.1970 -L 2 mg/kg BW CTLA4 ncl: p = 0.1970 -L 2 mg/kg BW CTLA4 ncl: p = 0.1970 -L 2 mg/kg BW CTLA4 ncl: p = 0.1970 -L 2 mg/kg BW CTLA4 ncl: p = 0.1970 -L 2 mg/kg BW CTLA4 ncl: p = 0.1970 -L 2 mg/kg BW CTLA4 ncl: p = 0.1970 -L 2 mg/kg BW CTLA4 ncl: p = 0.1970 -L 2 mg/kg BW CTLA4 ncl: p = 0.1970 -L 2 mg/kg BW CTLA4 ncl: p = 0.1970 -L 2 mg/kg BW CTLA4 ncl: p = 0.1970 -L 2 mg/kg BW CTLA4 ncl: p = 0.1970
	Cyclic	disru	ption c	f MEK im	proves ove	rall survival	with check	poin	t inł	nibitors (SITC 2022)

Corporate



Finance & Intellectual Property

Finance • Cash, cash equivalents and marketable securities as of December 31, 2022; \$105.5M • Cash runway into Q4 2024 supports: • IMM-1-104: • Multiple data readouts

- Multiple data readouts from Phase 1/2a trial
- IMM-6-415:
 Anticipate IND filing
- in Q4 2023 • Research in additional oncology programs

Intellectual Property

Patents issued/pending:

- Pending U.S. and ex-U.S. applications relating to IMM-1-104
- Pending U.S. provisional and PCT applications relating to IMM-6-415
- Issued U.S. patent and pending application relating to DCT
- Pending U.S. applications to Fluency

Expected patent expiration:

(excluding patent term adjustments, etc.)

- IMM-1-104 = 2041
- IMM-6-415 =
- DCT = 2039
- Fluency = 2039

23 2023 Corporate Presentation

(i) Immuneering



Investment Summary

"Our approach is different."

- Targeting **large Universal-RAS** patient population (1.5M) versus more limited approaches.
- Monotherapy vs combination
 therapy potential
- Deep cyclic inhibition achieved briefly but forcefully, due to combination of:
 - Manyfold higher C_{MAX} and
 short half life
- Approach designed to spare healthy cells and potential to limit adaptive resistance

24 2023 Corporate Presentation

"IMM-1-104 demonstrates Universal-RAS potential."

- Robust preclinica
 - Pancreatic Cance
 - (KRAS^{G12C)}
 - NSCLC (KRAS^{OL2}
 - CRC (KRAS^{G(2D)}
 - Melanoma (NRAS^{Q6IR}
 - And others
- Hypothesis for IMM-1-104 from proprietary model.
- Validated using proprietary bioinformatics & 3D tumor growth assays

"2023 is shaping up to be our breakout year."

- **First patient dosed** in Phase 1/2a trial of lead asset IMM-1-104 in November 2022.
- Patient enrollment ongoing; investigator enthusiasm high.
- Broad inclusion criteria facilitates rapid trial enrollment.
- Upcoming data readouts, beginning mid-2023
- Cash runway projected into Q4 2024

Appendix


i Immuneering

Nasdaq: IMRX

March 2023




Differentiation Versus Other MEK Inhibitors




Our Platform Converts Gene Expression to Counterintuitive Insigh


Goal: achieve broader activity and better tolerability in RAS and beyond mutant disease




Deep Cyclic Inhibition Confirmed Using Transcriptomics



28 2023 Corporate Presentation




Head-to-Head Comparison of IMM-1-104 Against FDA-Approved MEK Inhibitors: CRAF-Bypass Resistance



Head-to-Head Comparison of IMM-1-104 Against Binimetinib +/- Encorafenib in KRAS-G12S NSCLC Tumor Model


IMM-1-104 as compared to binimetinib monotherapy demonstrated greater tumor growth inhibition (TGI)



3] 2023 Corporate Presentation

Head-to-Head Comparison of IMM-1-104 versus Binimetinib +/- Encorafenib in BRAF-V600E Melanoma Tumor Model

IMM-1-104 as compared to binimetinib monotherapy demonstrated greater tumor growth inhibition (TGI)




32 2023 Corporate Presentation

Conclusions (NRAS mutant Melanoma)




33 2023 Corporate Presentation


RAS Mutation Profiles Within Select Tumor Indications




KRAS Mutant Pancreatic (PAAD): Translational Opportunity




NRAS Mutant Melanoma: Translational Opportunity



KRAS Mutant NSCLC (Adeno): Translational Opportunity



KRAS Mutant CRC: Translational Opportunity



Phase 1/2a Primary and Secondary Outcomes

Phase 1: Primary Outcomes

